Citi analyst Samantha Semenkow raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $33 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Buy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off
- Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook
- Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c
- Catalyst Pharmaceuticals sees FY26 revenue $615M-$645M, consensus $615.58M
- Is CPRX a Buy, Before Earnings?